nach oben

Breast Cancer Research and Treatment

Erschienen in:

01.05.2009 | Clinical Trial

Efficacy and safety of erlotinib in patients with locally advanced or metastatic breast cancer

verfasst von: Maura N. Dickler, Melody A. Cobleigh, Kathy D. Miller, Pamela M. Klein, Eric P. Winer

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 1/2009

Einloggen, um Zugang zu erhalten

Abstract

Purpose To evaluate the efficacy and safety of erlotinib in advanced breast cancer. Experimental design Multicenter, phase II study of erlotinib (150 mg orally daily). Cohort 1: progression after anthracyclines, taxanes, and capecitabine (n = 47). Cohort 2: progression after >1 chemotherapy for advanced-stage disease (n = 22). Primary endpoint was response rate (World Health Organization criteria). Secondary endpoints were safety, time to progression, and survival. Results One patient in each cohort (n = 2, 3.0%) had a partial response. Response duration was 17 weeks for the Cohort 1 patient and 32 weeks for the Cohort 2 patient. Median time to progression was 43 days for Cohort 1 (range 1–204) and 43 days for Cohort 2 (range 25–419). Common adverse events were diarrhea, rash, dry skin, asthenia, nausea, anorexia. Conclusion Erlotinib had minimal activity in unselected previously treated women with advanced breast cancer. Predictive factors are needed to identify breast cancer patients who may derive benefit from erlotinib treatment.

Arteaga CL (2002) Epidermal growth factor receptor dependence in human tumors: more than just expression? Oncologist 7(Suppl 4):31–39. doi:10.1634/theoncologist.7-suppl_4-31 PubMedCrossRef

Shepherd FA, Rodrigues Pereira J, Ciuleanu T et al (2005) Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353:123–132. doi:10.1056/NEJMoa050753 PubMedCrossRef

Moore MJ, Goldstein D, Hamm J et al (2007) Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 25:1960–1966. doi:10.1200/JCO.2006.07.9525 PubMedCrossRef

Erbitux^® [package insert 11/07]. ImClone Systems Incorporated, New York, NY; Bristol-Myers Squibb Company, Princeton, NJ

Vectibix™ [package insert 10/07]. Amgen Inc., Thousand Oaks, CA

Klijn JG, Berns PM, Schmitz PI, Foekens JA (1992) The clinical significance of epidermal growth factor receptor (EGF-R) in human breast cancer: a review on 5232 patients. Endocr Rev 13:3–17. doi:10.1210/er.13.1.3 PubMed

Sainsbury JR, Farndon JR, Needham GK, Malcolm AJ, Harris AL (1987) Epidermal-growth-factor receptor status as predictor of early recurrence of and death from breast cancer. Lancet 1:1398–1402PubMed

Suo Z, Risberg B, Kalsson MG et al (2002) EGFR family expression in breast carcinomas. c-erbB-2 and c-erbB-4 receptors have different effects on survival. J Pathol 196:17–25. doi:10.1002/path.1003 PubMedCrossRef

Piccart-Gebhart MJ, Procter M, Leyland-Jones B et al (2005) Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353:1659–1672. doi:10.1056/NEJMoa052306 PubMedCrossRef

10.

Romond EH, Perez EA, Bryant J et al (2005) Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353:1673–1684. doi:10.1056/NEJMoa052122 PubMedCrossRef

11.

Slamon DJ, Leyland-Jones B, Shak S et al (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783–792. doi:10.1056/NEJM200103153441101 PubMedCrossRef

12.

DiLeo A, Gomez H, Aziz Z et al (2007) Lapatinib (L) with paclitaxel compared to paclitaxel as first-line treatment for patients with metastatic breast cancer: a phase III randomized, double-blind study of 580 patients. J Clin Oncol 25:1011

13.

Geyer CE, Forster J, Lindquist D et al (2006) Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 355:2733–2743. doi:10.1056/NEJMoa064320 PubMedCrossRef

14.

Anido J, Matar P, Albanell J et al (2003) ZD1839, a specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, induces the formation of inactive EGFR/HER2 and EGFR/HER3 heterodimers and prevents heregulin signaling in HER2-overexpressing breast cancer cells. Clin Cancer Res 9:1274–1283PubMed

15.

Emlet DR, Brown KA, Kociban DL et al (2007) Response to trastuzumab, erlotinib, and bevacizumab, alone and in combination, is correlated with the level of human epidermal growth factor receptor-2 expression in human breast cancer cell lines. Mol Cancer Ther 6:2664–2674. doi:10.1158/1535-7163.MCT-07-0079 PubMedCrossRef

16.

Albain K, Elledge R, Gradishar W (2002) Open-label, phase II, multicenter trial of ZD 1839 (‘Iressa’) in patients with advanced breast cancer. San Antonio Breast Cancer Symposium (SABCS). Breast Cancer Res Treat 76(suppl 1):S33. Abstract 20

17.

Baselga J, Albanell J, Ruiz A et al (2005) Phase II and tumor pharmacodynamic study of gefitinib in patients with advanced breast cancer. J Clin Oncol 23:5323–5333. doi:10.1200/JCO.2005.08.326 PubMedCrossRef

18.

Modi S, D’Andrea G, Norton L et al (2006) A phase I study of cetuximab/paclitaxel in patients with advanced-stage breast cancer. Clin Breast Cancer 7:270–277PubMedCrossRef

19.

Lu JF, Eppler SM, Wolf J et al (2006) Clinical pharmacokinetics of erlotinib in patients with solid tumors and exposure-safety relationship in patients with non-small cell lung cancer. Clin Pharmacol Ther 80:136–145. doi:10.1016/j.clpt.2006.04.007 PubMedCrossRef

20.

Trotti A, Byhardt R, Stetz J et al (2000) Common toxicity criteria: version 2.0. an improved reference for grading the acute effects of cancer treatment: impact on radiotherapy. Int J Radiat Oncol Biol Phys 47:3–47

21.

Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205–216. doi:10.1093/jnci/92.3.205 PubMedCrossRef

22.

Cassella G (1986) Refining binomial confidence intervals. Can J Stat 14:113–129. doi:10.2307/3314658 CrossRef

23.

Meier P, Kaplan E (1958) Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457–481. doi:10.2307/2281868 CrossRef

24.

Cohen MH, Johnson JR, Chen YF, Sridhara R, Pazdur R (2005) FDA drug approval summary: erlotinib (Tarceva) tablets. Oncologist 10:461–466. doi:10.1634/theoncologist.10-7-461 PubMedCrossRef

25.

Gordon AN, Finkler N, Edwards RP et al (2005) Efficacy and safety of erlotinib HCl, an epidermal growth factor receptor (HER1/EGFR) tyrosine kinase inhibitor, in patients with advanced ovarian carcinoma: results from a phase II multicenter study. Int J Gynecol Cancer 15:785–792. doi:10.1111/j.1525-1438.2005.00137.x PubMedCrossRef

26.

Perez-Soler R, Chachoua A, Hammond LA et al (2004) Determinants of tumor response and survival with erlotinib in patients with non—small-cell lung cancer. J Clin Oncol 22:3238–3247. doi:10.1200/JCO.2004.11.057 PubMedCrossRef

27.

Baselga J (2002) Targeting the epidermal growth factor receptor with tyrosine kinase inhibitors: small molecules, big hopes. J Clin Oncol 20:2217–2219. doi:10.1200/JCO.2002.03.100 PubMedCrossRef

28.

Carey LA, Mayer E, Marcom PK et al (2007) EGFR inhibition with cetuximab in metastatic triple negative (basal-like) breast cancer. Abstract from BCRT Proceedings. Breast Cancer Res Treat 106(suppl 1):S32. Abstract 307

29.

Shigematsu H, Lin L, Takahashi T et al (2005) Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst 97:339–346PubMedCrossRef

30.

Eberhard DA, Johnson BE, Amler LC et al (2005) Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol 23:5900–5909. doi:10.1200/JCO.2005.02.857 PubMedCrossRef

31.

Di Fiore F, Blanchard F, Charbonnier F et al (2007) Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by cetuximab plus chemotherapy. Br J Cancer 96:1166–1169. doi:10.1038/sj.bjc.6603685 PubMedCrossRef

32.

Khambata-Ford S, Garrett CR, Meropol NJ et al (2007) Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J Clin Oncol 25:230–237. doi:10.1200/JCO.2006.10.5437 CrossRef

33.

Lievre A, Bachet JB, Le Corre D (2006) KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 66:3992–3995. doi:10.1158/0008-5472.CAN-06-0191 PubMedCrossRef

34.

Amado RG, Wolf M, Peeters M et al (2008) Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 26:1626–1634. doi:10.1200/JCO.2007.14.7116 PubMedCrossRef

35.

http://www.sanger.ac.uk/genetics/CGP/cosmic/

36.

Polychronis A, Sinnett HD, Hadjiminas D et al (2005) Preoperative gefitinib versus gefitinib and anastrozole in postmenopausal patients with oestrogen-receptor positive and epidermal-growth-factor-receptor-positive primary breast cancer: a double-blind placebo-controlled phase II randomised trial. Lancet Oncol 6:383–391. doi:10.1016/S1470-2045(05)70176-5 PubMedCrossRef

37.

Arteaga CL, O’Neil A, Moulder SL (2004) ECOG1100: a phase I-II study of combined blockade of the erbB receptor network with trastuzmab and gefitinib (‘Iressa’) in patients (pts) with HER2-overexpressing metastatic breast cancer (met br ca). Proceedings BCRT (SABCS 2004). Breast Cancer Res Treat 88:S15. Abstract 25

38.

Smith IE, Walsh G, Skene A et al (2007) A phase II placebo-controlled trial of neoadjuvant anastrozole alone or with gefitinib in early breast cancer. J Clin Oncol 25:3816–3822. doi:10.1200/JCO.2006.09.6578 PubMedCrossRef

39.

Bishop PC, Myers T, Robey R et al (2002) Differential sensitivity of cancer cells to inhibitors of the epidermal growth factor receptor family. Oncogene 21:119–127. doi:10.1038/sj.onc.1205028 PubMedCrossRef

40.

Yamasaki F, Zhang D, Bartholomeusz C et al (2007) Sensitivity of breast cancer cells to erlotinib depends on cyclin-dependent kinase 2 activity. Mol Cancer Ther 6:2168–2177. doi:10.1158/1535-7163.MCT-06-0514 PubMedCrossRef

41.

Jones HE, Goddard L, Gee JM et al (2004) Insulin-like growth factor-I receptor signalling and acquired resistance to gefitinib (ZD1839; Iressa) in human breast and prostate cancer cells. Endocr Relat Cancer 11:793–814. doi:10.1677/erc.1.00799 PubMedCrossRef

Titel: Efficacy and safety of erlotinib in patients with locally advanced or metastatic breast cancer
verfasst von: Maura N. Dickler
Melody A. Cobleigh
Kathy D. Miller
Pamela M. Klein
Eric P. Winer
Publikationsdatum: 01.05.2009
Verlag: Springer US
Erschienen in: Breast Cancer Research and Treatment / Ausgabe 1/2009
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-008-0055-9

Springer Medizin

Efficacy and safety of erlotinib in patients with locally advanced or metastatic breast cancer

Abstract

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2009

PE38KDEL-loaded anti-HER2 nanoparticles inhibit breast tumor progression with reduced toxicity and immunogenicity

Polymorphism of XRCC1 (at codon 399) and susceptibility to breast cancer, a meta-analysis of the literatures

Ethnic differences in the use of regular mammography: the multiethnic cohort

No association of TGFB1 L10P genotypes and breast cancer risk in BRCA1 and BRCA2 mutation carriers: a multi-center cohort study

The BARD1 Cys557Ser polymorphism and breast cancer risk: an Australian case–control and family analysis

Screening caused rising incidence rates of ductal carcinoma in situ of the breast

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie